Blog
RSS FeedPosted by Michael Wonder on 09 Nov 2019
Janssen announces Health Canada approval of Imbruvica (ibrutinib) in combination with obinutuzumab for treatment naïve patients with chronic lymphocytic leukaemia
8 November 2019 - Patients experienced a 77% reduction in risk of disease progression or death compared to chlorambucil plus obinutuzumab. ...
Posted by Michael Wonder on 31 Oct 2019
Janssen announces Health Canada approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are transplant ineligible
30 October 2019 - This Darzalex combination regimen reduced the risk of disease progression or death by 44% in newly ...
Posted by Michael Wonder on 16 Oct 2019
Health Canada approves Ipsen's Cabometyx (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma
15 October 2019 - Cabometyx demonstrated a statistically significant, 52% reduction in the risk of progression or death compared with sunitinib, ...
Posted by Michael Wonder on 09 Oct 2019
Health Canada approves Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
8 October 2019 - Approval of the highly selective Bruton's tyrosine kinase inhibitor in mantle cell lymphoma marks AstraZeneca's entry ...
Posted by Michael Wonder on 28 Sep 2019
Health Canada approves Tecentriq in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer
27 September 2019 - New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that ...
Posted by Michael Wonder on 14 Aug 2019
Health Canada approves Tecentriq (atezolizumab), first new treatment in 20 years for aggressive form of lung cancer
13 August 2019 - Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung ...
Posted by Michael Wonder on 31 Jul 2019
Health Canada approves Vitrakvi (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion
30 July 2019 - Bayer announced today that there is now a treatment in Canada for tyrosine receptor kinase fusion ...
Posted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...
Posted by Michael Wonder on 11 Jul 2019
Health Canada approves Pomalyst-based triplet combination for patients with multiple myeloma
10 July 2019 - Pomalyst in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple ...
Posted by Michael Wonder on 27 Jun 2019
Knight announces filing of new drug submission for Ibsrela in Canada
26 June 2019 - Knight Therapeutics announced today that Knight's new drug submission for Ibsrela (tenapanor) has been accepted for ...
Posted by Michael Wonder on 12 Jun 2019
Sask. Cancer Agency started chemotherapy drug trial without required Health Canada approval
11 June 2019 - Agency says it 'proactively' paused trial 5 months after it started. ...
Posted by Michael Wonder on 30 May 2019
Health Canada approves Tecentriq (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
29 May 2019 - Data show this new option can help some patients with metastatic non-small cell lung cancer live significantly ...
Posted by Michael Wonder on 09 May 2019
First and only PARP inhibitor, Lynparza (olaparib) approved as a first-line maintenance therapy treatment in BRCA mutated advanced ovarian cancer
8 May 2019 - AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to ...
Posted by Michael Wonder on 04 May 2019
Seattle Genetics announces progress in expanding Adcentis (brentuximab vedotin) indications in Canada
3 May 2019 - Health Canada approves Adcetris in combination with AVD chemotherapy for the treatment of previously untreated Hodgkin's lymphoma ...
Posted by Michael Wonder on 12 Apr 2019
Health Canada issues Notice of Compliance with Conditions for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinom
11 April 2019 - Cutaneous squamous cell carcinoma is the second most common skin cancer in Canada. ...